-transparent.png){kind=logo}
OBJECTIVE The efficient transduction of appropriate target cells will be critical for gene therapy. We evaluated the suitability of hemagglutinating virus of Japan (HVJ)-liposome-mediated gene transfer for gene therapy of liver diseases. METHODS The Escherichia coli beta-galactosidase (beta-gal) gene was introduced into rat liver by HVJ-liposome to examine gene transfer efficacy and persistence of expression with or without partial hepatectomy prior to transfection. RESULTS About 30% of hepatocytes were transduced after portal vein injection. Gene expression was transient, with only 2% of hepatocytes expressing beta-gal after 4 weeks. However, partial hepatectomy performed 24 h prior to injection resulted in persistently high levels of beta-gal for 4 weeks after injection. A 247-bp beta-gal polymerase chain reaction fragment transcript was detected in livers of transfected rats, but not in livers of control rats. The rat livers following gene transfer were histologically normal, and serum glutamic-pyruvic transaminase was not found to be elevated in rats. CONCLUSIONS Our results demonstrate that HVJ-liposome-mediated gene transfer produced high gene transduction and persistent gene expression in the liver.
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
February 2000,
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
June 1997,
The Annals of thoracic surgery,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
October 1991,
Proceedings of the National Academy of Sciences of the United States of America,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
July 1994,
Human gene therapy,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
September 2002,
[Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
June 2003,
Biochimica et biophysica acta,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
February 1997,
Biochemical and biophysical research communications,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
June 1996,
Gene therapy,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
December 2005,
Transplantation,
T Hirano, and
J Fujimoto, and
T Ueki, and
H Yamamoto, and
M Takeuchi, and
E Okamoto, and
H Takahashi, and
R Morisita, and
Y Sawa, and
Y Kaneda
August 1997,
Human gene therapy,
